Enovis Corporation (NYSE:ENOV – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $44.50.
ENOV has been the subject of several research reports. William Blair initiated coverage on shares of Enovis in a research report on Friday, April 17th. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. Evercore reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Enovis in a research report on Friday, May 8th. Finally, Zacks Research cut shares of Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st.
Check Out Our Latest Analysis on Enovis
Enovis Stock Performance
Enovis (NYSE:ENOV – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same quarter last year, the firm posted $0.81 EPS. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts forecast that Enovis will post 3.65 earnings per share for the current year.
Hedge Funds Weigh In On Enovis
Several large investors have recently added to or reduced their stakes in ENOV. California State Teachers Retirement System boosted its holdings in Enovis by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock worth $1,622,000 after acquiring an additional 621 shares during the last quarter. MGO One Seven LLC boosted its holdings in Enovis by 9.4% during the 4th quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock worth $202,000 after acquiring an additional 650 shares during the last quarter. Rhumbline Advisers boosted its holdings in Enovis by 0.4% during the 3rd quarter. Rhumbline Advisers now owns 173,023 shares of the company’s stock worth $5,250,000 after acquiring an additional 682 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares during the last quarter. Finally, Empowered Funds LLC boosted its holdings in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after acquiring an additional 749 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.
Enovis Company Profile
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Recommended Stories
- Five stocks we like better than Enovis
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
